Pharmaceuticals company Marksans Pharma announced Q1FY26 results Operating revenue stood at Rs 620 crore, up by 5% YoY, driven mainly by growth in the US market from new product launches in the gastrointestinal, pain management, and digestive health segments. Gross profit stood at Rs 358.2 crore, up by 8.9% YoY, with a gross margin expansion of 209 bps YoY to 57.8%. Gross margin improved with the liquidation of higher-cost inventories and benefits from softening input costs. EBITDA stood at Rs 100.1 crore, with a margin of 16.1%. EPS was at Rs 1.3. Mark Saldanha, Managing Director, said: “While Q1FY26 was a seasonally soft quarter, we delivered year-on-year revenue growth of 5%, while gross profit increased by 8.9%. This was supported by successful new product launches in the US markets and the easing of raw material costs. While EBITDA and net profit margins were impacted by ramp-up costs, a one-time ECL provision for the emerging market division, and forex adjustments, these are transient and do not affect the fundamental momentum of our business. We are already seeing encouraging early signs of demand recovery in key markets such as the US, the UK, and Australia. With the Goa facility integration nearing completion, we are now sharply focused on scaling capacity, enhancing operational efficiency, and unlocking synergies. Our execution discipline, combined with a robust pipeline and expanding market presence, positions us well to deliver sustainable, long-term value. We remain committed to driving growth, improving returns, and creating enduring value for our stakeholders in FY26 and beyond.” Result PDF